Allarity shares jump 11.45% after-hours as VA-funded Phase 2 SCLC trial initiates dosing.

Allarity Therapeutics (ALLR) surged 11.45% in after-hours trading following the announcement that the first patients had been dosed in a VA-funded Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC). The trial, fully funded by the U.S. Department of Veterans Affairs and open at 11 VA sites, targets a high-unmet-need area where current treatment options are limited. Stenoparib’s dual PARP and WNT pathway inhibition is highlighted as a differentiated mechanism that may enhance temozolomide efficacy while reducing toxicity compared to first-generation PARP inhibitors. The CEO emphasized the trial’s rapid enrollment and the drug’s favorable safety profile, underscoring its potential to address aggressive SCLC with brain metastases. The VA’s financial backing and the trial’s focus on an underserved patient population likely drove investor optimism, aligning with the stock’s sharp after-hours gain.